Xencor | XNCR - Selling And Administration Expenses


Xencor reported $82.12M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Arrowhead Research USD 41.74M 4.28M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Xencor USD 82.12M 65.08M Mar/2026